Miyazaki Takuro, Sato Shuntaro, Kondo Takashi, Kusaka Mamoru, Gotoh Mitsukazu, Saiki Yoshikatsu, Ono Minoru, Kokudo Norihiro, Enosawa Shin, Satoh Shigeru, Soeda Etsuko, Furukawa Hiroyuki, Kobayashi Eiji, Nagayasu Takeshi
Department of Surgical Oncology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Clinical Research Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Surg Today. 2018 Jun;48(6):618-624. doi: 10.1007/s00595-018-1628-9. Epub 2018 Jan 29.
In Japan, there have been no national surveys on the incidence of de novo malignancy after solid organ transplantation, which is one of the leading causes of death in transplant recipients.
A questionnaire was distributed to institutions that perform solid organ transplantation in Japan, and clinical information was collected from patients who underwent transplantation between 2001 and 2010 and who exhibited de novo malignancies.
Nine thousand two hundred ten solid organ transplants (kidney, 49.9%; liver, 45.9%; heart, 0.9%; lung, 1.2%; pancreas, 1.9%; small intestine, 0.2%) were performed. Four hundred seventy-nine (5.2%) cases of de novo malignancy were identified. The transplanted organs of the patients included the kidney (n = 479, 54.8%), liver (n = 186, 38.8%), heart (n = 5, 0.1%), lung (n = 18, 3.8%), pancreas (n = 9, 1.9%), and small intestine (n = 1, 0.02%). The most common malignancies were post-transplant lymphoproliferative disorder (n = 87) and cancers of the kidney (n = 43), stomach (n = 41), large intestine (n = 41), and lung (n = 36).
This is the first national survey of the incidence of de novo malignancy in Japan. Further study is required to identify the risk of de novo malignancy in organ transplant recipients in comparison to the general population, namely the standardized incidence ratio.
在日本，尚未对实体器官移植后新发恶性肿瘤的发病率进行全国性调查，而实体器官移植是移植受者的主要死亡原因之一。
向日本进行实体器官移植的机构发放问卷，并从2001年至2010年接受移植且出现新发恶性肿瘤的患者中收集临床信息。
共进行了9210例实体器官移植（肾脏，49.9%；肝脏，45.9%；心脏，0.9%；肺，1.2%；胰腺，1.9%；小肠，0.2%）。确定了479例（5.2%）新发恶性肿瘤病例。患者移植的器官包括肾脏（n = 479，54.8%）、肝脏（n = 186，38.8%）、心脏（n = 5，0.1%）、肺（n = 18，3.8%）、胰腺（n = 9，1.9%）和小肠（n = 1，0.02%）。最常见的恶性肿瘤是移植后淋巴细胞增生性疾病（n = 87）以及肾癌（n = 43）、胃癌（n = 41）、大肠癌（n = 41）和肺癌（n = 36）。
这是日本首次对新发恶性肿瘤发病率进行的全国性调查。需要进一步研究以确定器官移植受者与普通人群相比新发恶性肿瘤的风险，即标准化发病率比。
